Ben Yehuda A, Lossos I S, Or R, Ben Chetrit E, Goldstein R H, Conner M W, Breuer R
Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
Pulm Pharmacol Ther. 1997;10(1):61-5. doi: 10.1006/pupt.1997.0076.
We have evaluated the effect of colchicine, a potential antifibrotic drug, on bleomycin-induced pulmonary inflammation in hamsters. Pulmonary injury was induced by a single intratracheal (IT) instillation of bleomycin (bleo). Four groups of male Syrian hamsters each received one of four treatments: (1) IT bleo and twice daily intraperitoneal (IP) injections of colchicine (col) starting one day before IT instillation of bleo (bleo-col); (2) IT bleo and IP injections of saline (bleo-sal); (3) IT saline and IP colchicine (sal-col); and (4) IT saline and IP saline (sal-sal). Animals were sacrificed 28 days after IT treatment. Lung injury was evaluated histologically, biochemically and by analysis of bronchoalveolar lavage (BAL) fluid. Treatment of hamsters with colchicine did not ameliorate the bleo-induced lung injury, as determined by a semiquantitative morphological index that assesses the severity and extent of the lung injury on a scale of 0-3. Lung hydroxyproline measurements and BAL fluid cell count were also similar in bleo-col compared to bleo-sal hamsters. Colchicine did not prevent the bleo-induced restriction expressed by volume displacement. These results indicate that colchicine does not ameliorate the bleo-induced lung inflammation and fibrosis and call for further controlled investigations to justify the use of this drug in pulmonary disorders.
我们评估了秋水仙碱(一种潜在的抗纤维化药物)对博来霉素诱导的仓鼠肺部炎症的影响。通过气管内(IT)单次注射博来霉素(bleo)诱导肺部损伤。四组雄性叙利亚仓鼠分别接受以下四种处理之一:(1)IT注射bleo,并在IT注射bleo前一天开始每天两次腹腔内(IP)注射秋水仙碱(col)(bleo-col);(2)IT注射bleo,并IP注射生理盐水(bleo-sal);(3)IT注射生理盐水,并IP注射秋水仙碱(sal-col);以及(4)IT注射生理盐水,并IP注射生理盐水(sal-sal)。IT处理后28天处死动物。通过组织学、生物化学以及支气管肺泡灌洗(BAL)液分析评估肺损伤。通过半定量形态学指数(该指数以0-3的等级评估肺损伤的严重程度和范围)确定,用秋水仙碱处理仓鼠并不能改善bleo诱导的肺损伤。与bleo-sal仓鼠相比,bleo-col仓鼠的肺羟脯氨酸测量值和BAL液细胞计数也相似。秋水仙碱不能预防bleo诱导的以体积位移表示的限制性改变。这些结果表明,秋水仙碱不能改善bleo诱导的肺部炎症和纤维化,需要进一步的对照研究来证明该药物在肺部疾病中的应用合理性。